Achondroplasia Treatment Market, by Treatment Type, by Route of Administration, by Distribution Channel, and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030
Achondroplasia is a form of short-limbed dwarfism. Achondroplasia is characterized by an average-sized trunk, short arms and legs, notably short upper arms and thighs, a limited range of motion at the elbows, and an enlarged head. Spinal stenosis, a narrowing of the spinal canal that can compress the upper section of the spinal cord, is a potentially serious complication of achondroplasia. Spinal stenosis is characterized by leg pain, tingling, and weakness, which can make walking difficult. Achondroplasia is caused by mutations in the FGFR3 gene. The FGFR3 gene is responsible for giving instructions when making a protein that is involved in the development and maintenance of bone and brain tissue.
Market Dynamics
Increasing approvals of achondroplasia treatment drugs by regulatory bodies are expected to drive the market growth over the forecast period. For instance, in November 2021, BioMarin, a global biotechnology company, announced that the U.S. Food and Drug Administration (FDA) had granted accelerated approval to VOXZOGO (vosoritide) for injection, indicated to increase linear growth in pediatric patients with achondroplasia of five years of age and older with open epiphyses (growth plates). Moreover, in August 2021, QED Therapeutics, a subsidiary of BridgeBio Pharma, Inc., announced that the European Commission (EC) had granted marketing authorization for VOXZOGO (vosoritide), a once-daily injection to treat achondroplasia in children from the age of 2 until growth plates are closed, which occurs after puberty when children reach final adult height.
Also, increasing research and development by key players for the treatment of achondroplasia is expected to drive the treatment segment growth over the forecast period. For instance, in November 2021, RIBOMIC, Inc., a clinical stage pharmaceutical company specialized in aptamer therapeutics, announced the results from its Phase 1, healthy volunteer clinical study using RBM-007 for the planned treatment of achondroplasia, which was completed in May 2021.
Key features of the study:
This report provides an in-depth analysis of the global achondroplasia treatment market and provides market size (US$ Million) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global Achondroplasia Treatment market based on the following parameters– Company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include BioMarin, RIBOMIC, Ascendis Pharma A/S, BridgeBio Pharma, Inc., Pfizer Inc., PhaseBio Pharmaceuticals, Inc., SiSaf, Novo Nordisk A/S, F. Hoffmann-La Roche Ltd, LG Chem, Ferring B.V., JCR Pharmaceuticals Co., Ltd, KVK TECH, INC., VIVUS LLC., ProLynx Inc., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Ipsen Pharma, Novartis AG, and Xiamen Amoytop Biotech Co., Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global achondroplasia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global achondroplasia treatment market.
Detailed Segmentation:
Global Achondroplasia Treatment Market, By Treatment Type:
Vosoritide
Human Growth Hormone
Others
Global Achondroplasia Treatment Market, By Route of Administration:
Oral
Parenteral
Global Achondroplasia Treatment Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Achondroplasia Treatment, By Region:
North America
U.S.
Canada
Latin America
Brazil
Mexico
Argentina
Rest of Latin America
Europe
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
GCC
Israel
Rest of Middle East
Africa
South Africa
Central Africa
North Africa
Company Profiles
BioMarin
RIBOMIC
Ascendis Pharma A/S
BridgeBio Pharma, Inc.
Pfizer Inc.
PhaseBio Pharmaceuticals, Inc.
SiSaf
Novo Nordisk A/S
F.Hoffmann-La Roche Ltd
LG Chem
Ferring B.V.
JCR Pharmaceuticals Co., Ltd
KVK TECH, INC.
VIVUS LLC.
ProLynx Inc.
Teva Pharmaceutical Industries Ltd.
Eli Lilly and Company
Ipsen Pharma
Novartis AG
Xiamen Amoytop Biotech Co., Ltd.
1. Research Objective and Assumption
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snapshot, By Treatment Type
Market Snapshot, By Route of Administration
Market Snapshot, By Distribution Channel
Market Snippet, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Restraints
Market Opportunities
Impact Analysis
Recent Drug Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis
4. Global Achondroplasia Treatment Market, COVID-19 Impact Analysis
Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand
5. Global Achondroplasia Treatment Market, By Treatment Type, 2018 – 2030 (US$ Mn)
Introduction
Market Share Analysis, 2023 and 2030 (%)
Y-o-Y Growth Analysis, 2018–2030
Segment Trends
Vosoritide
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn)
Human Growth Hormone
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn)
6. Global Achondroplasia Treatment Market, By Route of Administration, 2018 – 2030 (US$ Mn)
Introduction
Market Share Analysis, 2023 and 2030 (%)
Y-o-Y Growth Analysis, 2018–2030
Segment Trends
Oral
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn)
Parenteral
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn)
7. Global Achondroplasia Treatment Market, By Distribution Channel, 2018 – 2030 (US$ Mn)
Introduction
Market Share Analysis, 2023 and 2030 (%)
Y-o-Y Growth Analysis, 2018–2030
Segment Trends
Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn)
Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn)
Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018 – 2030, (US$ Mn)
8. Global Achondroplasia Treatment Market, By Regions, 2018 – 2030 (US$ Mn)
Introduction
Market Share Analysis, 2023 and 2030 (%)
Y-o-Y Growth Analysis, 2018–2030
Segment Trends
North America
Introduction
Market Size and Forecast, Y-o-Y Growth and By Treatment Type, 2018 – 2030, (US$ Mn)
Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 – 2030, (US$ Mn)
Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018 – 2030, (US$ Mn)
Market Size and Forecast, Y-o-Y Growth and By Country, 2018 – 2030, (US$ Mn)
U.S.
Canada
Europe
Introduction
Market Size and Forecast, Y-o-Y Growth and By Treatment Type, 2018 – 2030, (US$ Mn)
Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 – 2030, (US$ Mn)
Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018 – 2030, (US$ Mn)
Market Size and Forecast, Y-o-Y Growth and By Country, 2018 – 2030, (US$ Mn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
Introduction
Market Size and Forecast, Y-o-Y Growth and By Treatment Type, 2018 – 2030, (US$ Mn)
Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 – 2030, (US$ Mn)
Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018 – 2030, (US$ Mn)
Market Size and Forecast, Y-o-Y Growth and By Country, 2018 – 2030, (US$ Mn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
Introduction
Market Size and Forecast, Y-o-Y Growth and By Treatment Type, 2018 – 2030, (US$ Mn)
Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 – 2030, (US$ Mn)
Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018 – 2030, (US$ Mn)
Market Size and Forecast, Y-o-Y Growth and By Country, 2018 – 2030, (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
Introduction
Market Size and Forecast, Y-o-Y Growth and By Treatment Type, 2018 – 2030, (US$ Mn)
Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 – 2030, (US$ Mn)
Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018 – 2030, (US$ Mn)
Market Size and Forecast, Y-o-Y Growth and By Country, 2018 – 2030, (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
Introduction
Market Size and Forecast, Y-o-Y Growth and By Treatment Type, 2018 – 2030, (US$ Mn)
Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 – 2030, (US$ Mn)
Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018 – 2030, (US$ Mn)
Market Size and Forecast, Y-o-Y Growth and By Country, 2018 – 2030, (US$ Mn)
North Africa
Central Africa
South Africa
9. Competitive Landscape
Company Profiles
BioMarin
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
RIBOMIC
Ascendis Pharma A/S
BridgeBio Pharma, Inc.
Pfizer Inc.
PhaseBio Pharmaceuticals, Inc.
SiSaf
Novo Nordisk A/S
F.Hoffmann-La Roche Ltd
LG Chem
Ferring B.V.
JCR Pharmaceuticals Co., Ltd
KVK TECH, INC.
VIVUS LLC.
ProLynx Inc.
Teva Pharmaceutical Industries Ltd.
Ipsen Pharma
Novartis AG
Xiamen Amoytop Biotech Co., Ltd.
10. Section
References
Research Methodology
About us and Sales Contact
*Browse 30 market data tables and 24 figures on “Achondroplasia Treatment Market – Global forecast to 2030